stoxline Quote Chart Rank Option Currency Glossary
  
Cyclo Therapeutics, Inc. (CYTH)
1.2299  0.015 (1.23%)    07-16 10:58
Open: 1.2101
High: 1.2299
Volume: 5,329
  
Pre. Close: 1.215
Low: 1.2101
Market Cap: 35(M)
Technical analysis
2024-07-16 10:48:34 AM
Short term     
Mid term     
Targets 6-month :  1.51 1-year :  1.63
Resists First :  1.29 Second :  1.39
Pivot price 1.25
Supports First :  1.12 Second :  0.94
MAs MA(5) :  1.28 MA(20) :  1.24
MA(100) :  1.38 MA(250) :  1.43
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  35.8 D(3) :  56.2
RSI RSI(14): 45.3
52-week High :  2.11 Low :  0.88
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ CYTH ] has closed above bottom band by 36.0%. Bollinger Bands are 7.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.28 - 1.29 1.29 - 1.3
Low: 1.18 - 1.19 1.19 - 1.2
Close: 1.18 - 1.2 1.2 - 1.21
Company Description

Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of Alzheimer's disease. In addition, it sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is based in Gainesville, Florida.

Headline News

Sun, 14 Jul 2024
Brokerages Set PROCEPT BioRobotics Co. (NASDAQ:PRCT) PT at $61.20 - American Banking and Market News

Fri, 12 Jul 2024
Short Interest in Cyclo Therapeutics, Inc. (NASDAQ:CYTH) Grows By 148.7% - Defense World

Fri, 14 Jun 2024
Rafael Holdings Reports Third Quarter Fiscal 2024 Financial Results - StockTitan

Tue, 19 Mar 2024
Why Is Fusion Pharmaceuticals (FUSN) Stock Up 101% Today? - InvestorPlace

Mon, 25 Sep 2023
This biotech went public 3 years ago at $14 per share. Here's how its stock cratered to 27 cents - The Business Journals

Mon, 25 Sep 2023
Wilson Sonsini Advises Applied Molecular Transport Inc. in its Sale to Cyclo Therapeutics - Wilson Sonsini

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Drug Manufacturers - Specialty & Generic
Shares Out -11 (M)
Shares Float 0 (M)
Held by Insiders 2.861e+007 (%)
Held by Institutions 1.588e+007 (%)
Shares Short 0 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS 0
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -0.93
Profit Margin 0 %
Operating Margin -2 %
Return on Assets (ttm) 523.7 %
Return on Equity (ttm) -223.7 %
Qtrly Rev. Growth 663.9 %
Gross Profit (p.s.) 0
Sales Per Share 0.03
EBITDA (p.s.) -0.68
Qtrly Earnings Growth -2.014e+007 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)
Stock Valuations
PE Ratio 0
PEG Ratio 0
Price to Book value -1.33
Price to Sales 36.64
Price to Cash Flow 0
Stock Dividends
Dividend 11710
Forward Dividend 28420
Dividend Yield 959757%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android